{"contentid": 488041, "importid": NaN, "name": "Clinigen and Amgen agree multi-product distribution deal", "introduction": "UK-based Clinigen Group has signed a distribution agreement with Amgen to supply part of its product portfolio to multiple countries across Africa and Asia.", "content": "<p>UK-based Clinigen Group (AIM: CLIN) has signed a distribution agreement with Amgen (Nasdaq: AMGN) to supply part of its product portfolio to multiple countries across Africa and Asia.</p>\n<p>Clinigen, a global pharmaceutical products and services company, has in recent years pursued a strategy of acquiring global rights to certain assets targeted for their potential to be renewed and have access broadened.</p>\n<p>Under the terms of the distribution agreement, Clinigen will provide healthcare professionals in certain territories with access to medicines which are not currently on the market.</p>\n<p>Clinigen will act as the main point of contact for doctors seeking access to the medicines, managing orders and enquiry management, regulatory compliance, and logistics.</p>\n<p>Chief operating officer Sam Herbert said: &ldquo;We are pleased to be partnering with Amgen to supply this portfolio of medicines for patients with unmet medical needs.&rdquo;</p>\n<p>He added: &ldquo;This agreement will help to ensure healthcare professionals can obtain compliant access to critical medicines that are not commercially available in their country.&rdquo;</p>\n<h2>Products in the agreement</h2>\n<p>Blincyto (blinatumomab)<br />Kyprolis (carfilzomib)<br />Vectibixa (panitumumab)<br />Nplate (romiplostim)<br />Xgeva (denosumab)<br />Aranesp (darbepoetin alfa)<br />Neulasta (peg-filgrastim)<br />Neupogen (filgrastim)<br />Prolia (denosumab)<br />Repatha (evolocumab)</p>\n<p>&nbsp;</p>", "date": "2021-03-15 14:13:00", "meta_title": NaN, "meta_keywords": "Clinigen, distribution, Amgen, access, agreement, medicines, multi-product, deal, agree, global, product, Africa, countries, multiple, portfolio, part, AMG", "meta_description": "UK-based Clinigen Group (AIM: CLIN) has signed a distribution agreement with Amgen (Nasdaq: AMGN) to supply part of its product portfolio to multiple countries ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-15 14:11:20", "updated": "2021-03-15 14:35:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/clinigen-and-amgen-agree-multi-product-distribution-deal", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "clinigen-big.jpg", "image2id": "clinigen-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Musculoskeletal, Oncology", "topic_tag": "Deals, Licensing", "geography_tag": "Global, UK, USA", "company_tag": "Amgen, Clinigen", "drug_tag": "Aranesp, Blincyto, Kyprolis, Neulasta, Neupogen, Repatha, Xgeva", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-15 14:13:00"}